Transcriptional phenocopies of deleterious KEAP1 mutations correlate with survival outcomes in lung cancer treated with immunotherapy

免疫疗法 肺癌 癌症 生物 物候学 肿瘤科 表型 生存分析 STK11段 内科学 癌症研究 医学 基因 克拉斯 遗传学 结直肠癌
作者
Stefano Scalera,Biagio Ricciuti,Daniele Marinelli,Marco Mazzotta,Laura Cipriani,Giulia Bon,Giulia Schiavoni,Irene Terrenato,Alessandro Di Federico,Joao V. Alessi,Maurizio Fanciulli,Ludovica Ciuffreda,Francesca De Nicola,Frauke Goeman,Giulio Caravagna,Daniele Santini,Ruggero De Maria,Federico Cappuzzo,Gennaro Ciliberto,Mariam Jamal‐Hanjani
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:30 (19): 4397-4411
标识
DOI:10.1158/1078-0432.ccr-24-0626
摘要

Co-occurring mutations in KEAP1 and STK11/KRAS have emerged as determinants of survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with immunotherapy. However, these mutational contexts identify a fraction of nonresponders to immune checkpoint inhibitors. We hypothesized that KEAP1 wild-type tumors recapitulate the transcriptional footprint of KEAP1 mutations and that this KEAPness phenotype can determine immune responsiveness with higher precision compared to mutation-based models. The Cancer Genome Atlas was used to infer the KEAPness phenotype and explore its immunological correlates at the pan-cancer level. The association between KEAPness and survival outcomes was tested in two independent cohorts of patients with advanced NSCLC treated with immunotherapy and profiled by RNA sequencing (SU2C n = 153; OAK/POPLAR n = 439). The NSCLC TRACERx421 multiregion sequencing study (tumor regions, n = 947) was used to investigate evolutionary trajectories. KEAPness-dominant tumors represented 50% of all NSCLCs and were associated with shorter progression-free survival (PFS) and overall survival (OS) compared to KEAPness-free cases in independent cohorts of patients with NSCLC treated with immunotherapy (SU2C PFS P = 0.042, OS P = 0.008; OAK/POPLAR PFS P = 0.0014, OS P < 0.001). Patients with KEAPness tumors had survival outcomes comparable to those with KEAP1-mutant tumors. In the TRACERx421, KEAPness exhibited limited transcriptional intratumoral heterogeneity and immune exclusion, resembling the KEAP1-mutant disease. This phenotypic state occurred across genetically divergent tumors, exhibiting shared and private cancer genes under positive selection when compared to KEAP1-mutant tumors. We identified a KEAPness phenotype across evolutionary divergent tumors. KEAPness outperforms mutation-based classifiers as a biomarker of inferior survival outcomes in patients with NSCLC treated with immunotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lm发布了新的文献求助10
刚刚
CipherSage应助体贴汽车采纳,获得10
2秒前
两味愚发布了新的文献求助10
2秒前
3秒前
5秒前
小马甲应助GXLong采纳,获得10
5秒前
5秒前
CodeCraft应助柯米克采纳,获得10
5秒前
深情安青应助淡淡梦容采纳,获得10
6秒前
苏利文发布了新的文献求助30
7秒前
JayeChen完成签到,获得积分10
7秒前
7秒前
屈绮兰应助张张采纳,获得30
8秒前
ding应助玉小赤采纳,获得10
8秒前
9秒前
愉快的雪珍完成签到,获得积分10
10秒前
sylnd126发布了新的文献求助10
10秒前
10秒前
KK发布了新的文献求助10
11秒前
12秒前
14秒前
体贴汽车发布了新的文献求助10
14秒前
15秒前
能干冰露发布了新的文献求助10
15秒前
16秒前
17秒前
liz_应助mariawang采纳,获得10
17秒前
DT发布了新的文献求助10
17秒前
EED驳回了今后应助
18秒前
Orange应助酷酷的王采纳,获得10
18秒前
斯文败类应助达达尼尔采纳,获得10
18秒前
量子星尘发布了新的文献求助10
18秒前
19秒前
20秒前
Marjorie完成签到,获得积分10
20秒前
han应助写得出发的中采纳,获得10
20秒前
20秒前
淡淡梦容发布了新的文献求助10
20秒前
爆米花应助虚幻靖易采纳,获得10
21秒前
派大星完成签到,获得积分10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021